Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation

Cell Death and Differentiation

Volumn 22, Issue 2, 2015, Pages 311-322

  Kumari, A ^a,b   Iwasaki, T ^a,c   Pyndiah, S ^b,d   Cassimere, E K ^b,e   Palani, C D ^a,f   Sakamuro, D ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KOBE UNIVERSITY   (Japan)

^d INSERM   (France)

^e TEXAS SOUTHERN UNIVERSITY   (United States)

^f AUGUSTA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BIN1 PROTEIN, HUMAN; BIN1 PROTEIN, MOUSE; E2F1 PROTEIN, HUMAN; E2F1 PROTEIN, MOUSE; NERVE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR E2F1; TUMOR SUPPRESSOR PROTEIN;

3T3 CELL LINE; ANIMAL; APOPTOSIS; CELL DIVISION; CELL LINE; DNA DAMAGE; GENETICS; HUMAN; METABOLISM; MOUSE; PROMOTER REGION;

3T3 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE DIPHOSPHATE; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; DNA DAMAGE; E2F1 TRANSCRIPTION FACTOR; HUMANS; MICE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84939898136     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.146     Document Type: Article

References (55)

1. Guo XE, Ngo B, Modrek AS, Lee WH. Targeting tumor suppressor networks for cancer therapeutics. Curr Drug Targets 2014; 15: 2-16.
2. Orr B, Compton DA. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front Oncol 2013; 3: 164.
3. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012; 113: 433-439.
4. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560.
5. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
6. Johnson DG, Degregori J. Putting the oncogenic and tumor suppressive activities of E2F into context. Curr Mol Med 2006; 6: 731-738.
7. Stanelle J, Pützer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 2006; 12: 177-185.
8. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3: 552-558.
9. Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S et al. Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem 2002; 277: 39760-39768.
10. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4: 859-864.
11. Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J 2005; 24: 3724-3736.
12. del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, Bracken A et al. E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 2007; 6: 2697-2705.
13. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26: 464-469.
14. Cassimere EK, Pyndiah S, Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ 2009; 16: 1641-1653.
15. Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. J Cell Physiol 2008; 216: 621-631.
16. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
17. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin Jr WG, Livingston DM et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
18. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013; 14: 297-306.
19. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol 2013; 228: 1676-1687.
20. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13: 411-424.
21. Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Gene Dev 2012; 26: 417-432.
22. Ji Y, Tulin AV. The roles of PARP1 in gene control and cell differentiation. Curr Opin Genet Dev 2010; 20: 512-518.
23. Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE et al. Advances in using PARP inhibitors to treat cancer. BMC Med 2012; 10: 25.
24. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Samara R, Espinoza LA, Hassa PO et al. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene 2003; 22: 8460-8471.
25. Dantzer F, de La Rubia G, Ménissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000; 39: 7559-7569.
26. Kovesdi I, Reichel R, Nevins JR. Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci USA 1987; 84: 2180-2184.
27. Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 2011; 4: ra19.
28. Chiou SH, Jiang BH, Yu YL, Chou SJ, Tsai PH, Chang WC et al. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. J Exp Med. 2013; 210: 85-98.
29. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996; 14: 69-77.
30. Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene 1999; 18: 3564-3573.
31. Lundgaard GL, Daniels NE, Pyndiah S, Cassimere EK, Ahmed KM, Rodrigue A et al. Identification of a novel effector domain of BIN1 for cancer suppression. J Cell Biochem 2011; 112: 2992-3001.
32. Yelamos J, Farres J, Llacuna L, Ampurdanes C, Martin-Caballero J. PARP-1 and PARP-2: New players in tumour development. Am J Cancer Res 2011; 1: 328-346.
33. Szántó M, Brunyánszki A, Kiss B, Nagy L, Gergely P, Virág L et al. Poly(ADP-ribose) polymerase-2: emerging transcriptional roles of a DNA-repair protein. Cell Mol Life Sci 69: 4079-4092, 2012.
34. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 5588-5599.
35. DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res 2001; 61: 3151-3156.
36. Elliott K, Ge K, Du W, Prendergast GC. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 2000; 19: 4669-4684.
37. Casal E, Federici L, Zhang W, Fernandez-Recio J, Priego EM, Miguel RN et al. The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry 2006; 45: 12917-12928.
38. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics 2006; 22: 195-201.
39. Kelley LA, Sternberg MJE. Protein structure prediction on the web: a case study using the Phyre server. Nat Protocol 2009; 4: 363-371.
40. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 1999; 96: 9689-9694.
41. Ge K, Duhadaway J, Sakamuro D, Wechsler-Reya R, Reynolds C, Prendergast GC. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 2000; 85: 376-383.
42. Ge K, Minhas F, Duhadaway J, Mao N-C, Wilson D, Buccafusca R et al. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000; 86: 155-161.
43. Ghaneie A, Zemba-Palko V, Itoh H, Itoh K, Sakamuro D, Nakamura S et al. Bin1 attenuation in breast cancer is correlated to nodal metastasis and reduced survival. Cancer Biol Ther 2007; 6: 192-194.
44. Chang MY, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ et al. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 2007a; 67: 100-107.
45. Chang MY, Boulden J, Katz B, Wang L, Meyer TJ, Soler AP et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 2007b; 67: 7605-7612.
46. Prendergast GC, Muller AJ, Ramalingam A, Chang MY. BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta 2009; 1795: 25-36.
47. Prokic I, Cowling BS, Laporte J. Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (Berl) 2014; 92: 453-463.
48. Kingwell K. Alzheimer disease: BIN1 variant increases risk of Alzheimer disease through tau. Nat Rev Neurol 2013; 9: 184.
49. Tan MS, Yu JT, Tan L. Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. Trends Mol Med 2013; 19: 594-603.
50. Hong T, Yang H, Zhang SS, Cho HC, Kalashnikova M, Sun B et al. Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia. Nat Med 2014; 20: 624-632.
51. Hong TT, Smyth JW, Chu KY, Vogan JM, Fong TS, Jensen BC et al. BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. Heart Rhythm 2012; 9: 812-820.
52. Hong TT, Cogswell R, James CA, Kang G, Pullinger CR, Malloy MJ et al. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2012; 9: 961-967.
53. Münger K, Yee CL, Phelps WC, Pietenpol JA, Moses HL, Howley PM. Biochemical and biological differences between E7 oncoproteins of the high-and low-risk human papillomavirus types are determined by amino-terminal sequences. J Virol 1991; 65: 3943-3948.
54. Wechsler-Reya RJ, Sakamuro D, Zhang J, Duhadaway J, Prendergast GC. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing. J Biol Chem 1997; 272: 31453-31458.
55. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51: 6581-6591.